4502.T
Takeda Pharmaceutical
Healthcare · Pharmaceuticals · TSE
$5,082.00
Data: 2026-06-14
✓ ETHICAL PASS
Unknown MOAT
HIGH
Data Confidence: 100.0%
Market Regime
Analysis pending
Today's Read
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
2026-07-03
Full Daily Analysis
Key Metrics
How this company measures up on the fundamentals that matter
Market Cap
$8.0T
Total market value of the company
42.55
Expensive — high growth expected
36.20
Based on estimated future earnings — lower means cheaper
Rev Growth
+3.9%
Year-over-year revenue change
Profit Margin
4.3%
How much profit the company keeps from each dollar of revenue
2.6%
Return on equity — how efficiently it uses shareholder money
Analyst Target
$6,000.00
+18% from current price — median analyst estimate
Recommendation
BUY
Consensus view from 15 analysts covering this stock
About Takeda Pharmaceutical
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba Fiber, Recombi
https://www.takeda.com
Country: Japan Industry: Drug Manufacturers - Specialty & Generic
Ethical Screening
Five compliance checks based on AAOIFI standards — all must pass for ethical clearance
Business Activity
PASS
Core business does not involve prohibited activities
Debt Ratio
31.7% PASS
Debt must be below 33% of total assets
Cash Ratio
2.7% PASS
Interest-bearing cash below 33% of assets
Receivables
5.4% PASS
Receivables below 49% of assets
Revenue Purity
2.7% PASS
Non-compliant revenue below 5% — any excess requires purification
Valuation
$1,684.65
What our model estimates this business is worth per share
-199.8%
Trading above fair value — no margin of safety
Rating
AVOID
Overall assessment combining ethics, valuation, and quality
69.6th
Ranks in the top 30% of our 13,571 screened universe
Trading at $5213, 209% above fair value of $1685. Passes all ethical screens. Ranks better than 43% of screened stocks.
Quantitative Intelligence
Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data
DISTRIBUTION
Smart money appears to be selling into strength — caution
0.835
Good returns relative to risk taken
0.0637
Suggested allocation is meaningful — the edge justifies a position
1.140
Returns exceed worst-case losses — strong risk profile
Annual Return
16.1%
Historical annualised return based on price data
-14.1%
Largest peak-to-trough decline — the worst it has been
BEAR
Statistical model detects bearish conditions
Days in State
15
How long the current regime has persisted — longer means more stable
Market Data
Trading characteristics and market positioning
0.09
Very low correlation to market moves
52W High
$6,033.00
16% below the year high
52W Low
$4,102.00
24% above the year low
Avg Volume
4,431,130
Average daily shares traded — higher means easier to buy and sell
N/A
Days it would take all short sellers to cover — higher means more crowded
401.0%
Annual dividend as a percentage of the share price
$119.43
Earnings per share over the last 12 months
Financial Health
Balance sheet strength and cash generation — the foundation of long-term value
70.14
Heavy leverage — higher financial risk if revenues decline
Quick Ratio
N/A
Like current ratio but excludes inventory — stricter test
Gross Margin
65.1%
Revenue left after cost of goods — higher means pricing power
Operating Margin
3.1%
Profit from core operations before interest and tax
$356.6B
Positive — the business generates more cash than it spends
Revenue (TTM)
$4.5T
Total revenue over the last 12 months
Net Income
$191.8B
Profitable — the bottom line is positive
What If You'd Bought 4502.T?
| Period |
Price Then |
Price Return |
Divs/Share |
$1,000 Became |
Total Return |
| 1 Month |
$5,162.00 |
-1.8% |
— |
$982 |
-1.8% |
| 2 Months |
$5,732.00 |
-11.6% |
— |
$885 |
-11.6% |
| 3 Months |
$5,568.00 |
-8.9% |
$100.00 |
$929 |
-7.1% |
| 6 Months |
$4,371.84 |
+16.0% |
$100.00 |
$1,183 |
+18.3% |
| 1 Year |
$4,193.59 |
+20.9% |
$200.00 |
$1,257 |
+25.7% |
| 2 Years |
$3,894.96 |
+30.2% |
$396.00 |
$1,403 |
+40.3% |
| 3 Years |
$3,997.86 |
+26.8% |
$584.00 |
$1,414 |
+41.4% |
| 5 Years |
$3,028.59 |
+67.4% |
$944.00 |
$1,986 |
+98.6% |
Dividends Collected Per Share
1 Year: $200.0000
3 Years: $584.0000
5 Years: $944.0000
$1,000 invested 1 year ago = 0.2 shares = $47.69 in dividends collected
Historical returns. Past performance does not guarantee future results. Prices from market close data.
Framework Review History
Timestamped framework reads — tracking how the analysis evolves over time
2026-07-03
DISTRIBUTION $5,082.00
+0.0% Review #2
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
2026-07-02
DISTRIBUTION $5,082.00
Review #1
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
Latest Analysis — 4502.T
Timestamped intelligence from our daily research pipeline
Analysis
4502-T Case Study — Framework Read | 2 July 2026
4502.T Case Study: Takeda Pharmaceutical | Titan Macro Desk * { margin: 0; padding: 0; box-sizing: border-box; } body { background: #0a0e14; color: #e0e0e0; font-family: 'Segoe UI', Arial, sans-serif; line-height:...
Want deeper analysis on Takeda Pharmaceutical?
Our framework analyses 4502.T daily across 19 analytical perspectives — positioning, macro, sentiment, volatility, options, sector rotation, and more. Members get the read 24 hours before anyone else.
Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-14